Thursday, May 19, 2016

A New Sex Drug For Women

In August the FDA approved Addyl to treat hypoactive sexual desire or lack of libido in women. Unlike Viagra, which addresses the physical issue of erectile dysfunction in men, Addyl tweaks the brain's mix of dopamine and serotonin, It must be taken daily and may take two months to be fully effective.

The results are not impressive. Only 10% of the women in the trial had a marked response and there were significant side effects. The critiques of its effectiveness and side effects have triggered discussions about desire and what triggers it. This may lead to more new drugs for lack of libido in the future. We will keep you informed.

Wednesday, May 18, 2016

The Secret To Living Longer

Live Longer Live Healthier

The recent longevity issue of time magazine has new and exciting news about health and longevity. The attention getting title is that it;s the little things that matter. It goes on to state that  new science shows that the daily choices you make can help you live better and longer. This latest science is showing that extending life is attainable for many of us with just a few small changes that are not hard to do and won't make you miserable.

Is this exciting news? Yes! Is this new news? Absolutely not. In our first book TriEnergetics we pointed out a way to get healthier. It was based upon making simple changes in what you ate, how you moved your body and how to manage the stress in your life.

In the sequel Live Longer Live Healthier we added to the program with additional information. Our intent was to  show that making these simple changes could have a profound effect on your health. These principles are as valid today as they were when we wrote the books. Read the books, decide for yourself and move on to better health and longevity

Get more information in our book Live Longer Live Healthier

or visit our website at

Tuesday, May 17, 2016

A New Treatment For Parkinson's Disease

Dr. James Parkinson first described the shaking palsy in 1817 a  collection of symptoms that we now call Parkinson's disease. Now some 200 years later this disease that affects one million Americans still has not been cured.

There are some treatments such as L-dopa and surgeries such as deep brain stimulation that help manage the symptoms, but all attempts to stop or reverse the disease have failed.

There is new research on a simple protein alpha-synuclein that points to a possible break through.
The working theory is that alpha-synuclein forms sticky clumps called amyloid that jump from brain cells to brain cell killing cells. This is particularly true for nerve cells that make the neural transmitter dopamine. When 70% of these dopamine cells are destroyed the patient starts displaying the symptoms of Parkinson's disease.

Researchers are working on a number of alpha-synuclein busting agents. Several of them will begin clinical trials in the next few years. If given early enough such agents might prevent the development of Parkinson's disease. Of course this  treatment may not pan out, but that is the natural course of research. Never the less it is an exciting concept. We will give you updates as they develop.